SkylineDx, an innovative diagnostics company specializing in the research, development and commercialization of molecular diagnostics for dermatology and oncology, announced the continued expansion of its direct commercial and clinical presence in the United States, marking a significant milestone in the company's commitment to supporting clinicians and expanding patient access to Merlin CP-GEP¹.
When SkylineDx initially began commercializing Merlin CP-GEP in the United States, the company utilized third-party distribution and licensing collaborations to establish market access and introduce the test to U.S. clinicians. In early 2025, SkylineDx made the strategic decision to transition to a direct commercial model and invest in its own U.S.-based sales, marketing and clinical organization.
That initial build-out is now complete; SkylineDx has concluded its third-party U.S. commercialization collaborations and has now established a fully integrated direct commercial organization responsible for supporting healthcare professionals, institutions, and patients across the country. With this foundation in place, SkylineDx continues to expand its commercial capabilities and geographic reach to support the growing adoption of Merlin CP-GEP.
The expansion reflects SkylineDx's belief that bringing an innovative molecular diagnostic into clinical practice requires more than making a test commercially available. It requires direct engagement with clinicians, responsive clinical and operational support, education around the scientific evidence, and a long-term commitment to the institutions and healthcare professionals incorporating the technology into patient care.
"Our strategy is straightforward: if we want clinicians to have the highest level of service, scientific support and access to Merlin CP-GEP, we need to be directly invested in the market," said Dharminder Chahal, CEO of SkylineDx. "We have moved from three sales representatives in early 2025 to a multidisciplinary U.S. organization of more than 25 people, with most of that investment in professionals working directly with clinicians in key territories. This is not simply a commercial expansion—it represents our long-term commitment to the U.S. melanoma community."
